title: Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
abstract: This study was designed prospectively to evaluate the development of anti-p53 antibodies (Abs) in lung cancer patients in relation to their clinical outcome. Sera, derived from 125 lung cancer patients, consisting of 14 small cell lung cancers (SCLC) and 111 non-SCLCs (NSCLC), were surveyed. The p53-null human NSCLC cell line, NCI-H1299, transfected with a human mutant p53 gene was prepared as the source of p53 antigen for immunoblotting analyses to detect the presence of serum anti-p53 Abs. The control group included sera from 10 healthy adults and 14 patients with benign pulmonary diseases. Clinical data including staging and survival were recorded for statistical analyses. The anti-p53 Abs were found in 8% (10 of 125) of the lung cancer patients studied (8.1% of NSCLC versus 7.1% of SCLC patients), whereas none of the control sera had detectable anti-p53 Abs. The presence of anti-p53 Abs was closely associated with malignant pleural effusions (P = 0.001). The p53 Ab-positive patients had a worse prognosis than the p53 Ab-negative patients (P < 0.02; median survival, 20 versus 41 weeks). In both univariate and multivariate analyses, the tumor extension and probably the presence of anti-p53 Abs were significant predictors for cancer death. The development of anti-p53 Abs (n = 9) was also a predictor for poor survival in patients with malignant effusions (n = 51). In conclusion, the presence of serum anti-p53 Abs is closely associated with malignant pleural effusions in lung cancer patients. It may serve as a negative prognostic factor for survival independent of malignant pleural effusions and tumor staging.
authors.affiliation: Chest Department, Veterans General Hospital-Taipei, Taiwan.
authors.forename: C L
authors.initials: CL
authors.lastname: Lai
authors.forename: C M
authors.initials: CM
authors.lastname: Tsai
authors.forename: T T
authors.initials: TT
authors.lastname: Tsai
authors.forename: B I
authors.initials: BI
authors.lastname: Kuo
authors.forename: K T
authors.initials: KT
authors.lastname: Chang
authors.forename: H T
authors.initials: HT
authors.lastname: Fu
authors.forename: R P
authors.initials: RP
authors.lastname: Perng
authors.forename: J Y
authors.initials: JY
authors.lastname: Chen
mesh_terms: D000912:Antibodies, Neoplasm / Q000097:blood* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000276:immunology*; D018288:Carcinoma, Small Cell / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000276:immunology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D016066:Pleural Effusion, Malignant / Q000097:blood / Q000209:etiology / Q000276:immunology*; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53